Abediterol/Mometasone furoate

阿贝特罗/莫米松糠酸酯

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAbediterol/Mometasone furoate
Drug Alias Name阿贝特罗和莫米松糠酸酯Abediterol/ICS阿贝特罗/莫米松Abediterol/Mometasone阿贝特罗+莫米松糠酸酯 +[17] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionBeta-2 adrenergic receptor agonistsGlucocorticoid receptor agonists
TargetsBeta-2 adrenergic receptorGlucocorticoid receptor
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsYes AbediterolMometasone furoate
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A
Related LinksN/A